Paul Harris named Vice President for Research Informatics
Paul Harris, PhD, has been appointed to a new role as Vice President for Research Informatics at Vanderbilt University Medical Center.
Research fellowship for genetic counselors established at Vanderbilt
Vanderbilt University School of Medicine has received a grant to establish a research fellowship for genetic counselors that will prepare them to contribute more fully to the advancement of personalized medicine.
Holowatyj receives National Cancer Institute MERIT Award
Vanderbilt's Andreana Holowatyj, PhD, MSCI, has received the National Cancer Institute's Method to Extend Research in Time Award to support her ongoing investigation into how early-onset colorectal cancer and its treatments impact reproductive health.
Study finds a role for AI in drug repurposing pipeline
A research team led by Wei-Qi Wei, MD, PhD, reported their findings on February 26th in Nature Digital Medicine. Their study searched for new treatments for Alzheimer’s disease (AD) by asking ChatGPT whether any existing drugs used for other problems might help patients with AD. ChatGPT is a cloud-based artificial intelligence program, a so-called large language model that’s been optimized for chat.
After 40 years, genetics still surprises VUMC’s Nancy Cox
As she looks back on her 40-plus year career, what surprises Nancy Cox, PhD, an internationally known geneticist at Vanderbilt University Medical Center, is how much progress has been made, and yet how much more there is to learn about the role genetic variation plays in human disease.
This study will have two Phases: Phase 1a and Phase 1b. The goal of Phase 1a of this clinical
study is to learn more about the safety, tolerability and dosing of study drug KITE-197, in
participants with relapsed or refractory large B-cell lymphoma (r/rLBCL). The goal of Phase
1b of this clinical study is learn about the effectiveness of the recommended dose of
KITE-197 in participants with r/r LBCL.
The primary objectives of this study are:
Phase 1a: To evaluate the safety of KITE-197 in participants with r/r LBCL and determine the
target dose level for Phase 1b.
Phase 1b: To evaluate the efficacy of KITE-197 in participants with r/r LBCL as measured by
the complete remission (CR) rate.
Jonathan Brunger, Ph.D., M.S.
- Assistant Professor of Biomedical Engineering
Jonathan Brunger, Ph.D., M.S.
- Assistant Professor of Biomedical Engineering
jonathan.m.brunger@Vanderbilt.Edu
Research Program
Debra Friedman named deputy director of Vanderbilt-Ingram Cancer Center
DEBRA FRIEDMAN, MD, MS, HOLDER OF THE E. BRONSON INGRAM CHAIR IN PEDIATRIC ONCOLOGY, HAS BEEN NAMED DEPUTY DIRECTOR OF VANDERBILT-INGRAM CANCER CENTER (VICC).
Vanderbilt-Ingram Cancer Center earns NCI Merit Award
VANDERBILT-INGRAM CANCER CENTER (VICC) HAS EARNED A MERIT EXTENSION AWARD FROM THE NATIONAL CANCER INSTITUTE (NCI) IN RECOGNITION OF MORE THAN A DECADE OF SUSTAINED EXCEPTIONAL PROGRESS.
Vanderbilt’s Dr. W. Kimryn Rathmell to be appointed director of the National Cancer Institute
VANDERBILT’S W. KIMRYN RATHMELL, MD, PHD TO BE APPOINTED DIRECTOR OF THE NATIONAL CANCER INSTITUTE
